Abstract 

As of today, type 2 diabetes mellitus and its complications impose a significant burden on healthcare systems worldwide. Myocardial infarction stands as a leading cause of death among patients with type 2 diabetes mellitus due to macroangiopathy resulting from glucose metabolism disorders and endothelial damage [5]. Unfortunately, even with timely assistance, patients with myocardial infarction may develop mechanical complications such as cardiac aneurysm, posing serious risks of myocardial wall rupture with a high likelihood of fatality. In most cases, interventricular septal rupture occurs, manifesting in 0,21% of cases of ST-segment elevation myocardial infarction (STEMI) and 0,04% of cases of non-STEMI. Surgical correction of the defect remains the only effective treatment method, albeit associated with a high risk of mortality. Consequently, intra- and post-operative complications in such patients prompt the search for alternative treatment modalities, including transcatheter closure of the defect [6].

Interventricular septal rupture more commonly occurs in older patients, women, those with hypertension, and chronic kidney disease. Typically, the defect arises against the backdrop of the first myocardial infarction in the absence of timely or absent reperfusion therapy. Interventricular septal rupture may develop within 1–14 days after STEMI. However, the incidence usually demonstrates a bimodal peak within the first 24 hours or 3–5 days after the infarction [12].

A clinical case of a patient with combined cardiometabolic pathology, namely, severe type 2 diabetes mellitus and post-infarction interventricular septal defect, is presented. The case underscores the issue of comorbidity in severe patients. Successful treatment of the patient was achieved through collaborative efforts of cardiac surgeons, intensivists, cardiologists and endocrinologists.

Key words: type 2 diabetes mellitus, myocardial infarction, post-infarction aneurysm, interventricular septal rupture

References:

1. Dohtiar VV, Jovnir B A, Buhney N O, Metodika profilactiki neyrovaskulyarnih uskladnen v cardiologiyi. Pain, anaesthesia & intensive care, (4(89), 33(2019). https:// doi.org/10.25284/2519-2078.4(89).2019.187806
2. Baviera, M., Genovese, S., Colacioppo, P. et al. Diabetes mellitus duration and mortality in patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol 21, 223 (2022). https://doi.org/10.1186/s12933-022-01655-w
3. Bromage, D.I., Godec, T.R., Pujades-Rodriguez, M. et al. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovasc Diabetol 18, 168 (2019). https:// doi.org/10.1186/s12933-019-0972-4
4. Carol Hodgson, Dale Needham, Kimberley Haines, Michael Bailey, Alison Ward, Megan Harrold, Paul Young, Jennifer Zanni, Heidi Buhr, Alisa Higgins, Jeff Presneill, Sue Berney. Feasibility and interrater reliability of the ICU Mobility Scale. Heart & Lung: The Journal of Acute and Critical Care, Elsevier. January–February 2014. DOI: https://doi. org/10.1016/j.hrtlng.2013.11.003
5. Cui J, Liu Y, Li Y, Xu F, Liu Y. Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective. Front Cardiovasc Med. 2021 Feb 24;8:644189. doi: 10.3389/ fcvm.2021.644189. PMID: 33718461; PMCID: PMC7943438.
6. David, T. Post-infarction ventricular septal rupture, Annals of Cardiothoracic Surgery journal, vol. 11, No 3, 2022.
7. HeL,WangJ,PingF,YangN,HuangJ,LiY,XuL,LiW,Zhang 
   Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 May 1;182(5):513-519. doi: 10.1001/jamainternmed.2022.0338. PMID: 35344001; PMCID: PMC8961394.
8. Hu Y, Lei M, Ke G, Huang X, Peng X, Zhong L, Fu P. Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients with Chronic Kidney Disease-A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020 Oct 7; 11:559446. doi: 10.3389/fendo.2020.559446. PMID: 33117278; PMCID: PMC7575818.
9. Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, Katherine R. Tuttle, Joshua J. Neumiller, Connie M. Rhee, Sylvia E. Rosas, Peter Rossing, George Bakris; Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 1 December 2022; 45 (12): 3075– https://doi. org/10.2337/dci22-0027
10. Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ. Do sulfonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol 2018; 6:821–832
11. Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020; 141(2): p.90-99. Doi: 10.1161/Circulationaha.119.044138
12. Mahajan K, Shah N, Patel H. Postinfarction Ventricular Septal Rupture. [Updated 2022 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.
13. Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas, John B. Buse; Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 1 November 2022; 45 (11): 2753– https://doi.org/10.2337/dci22-0034
14. National Institute of Diabetes and Digestive and Kidney Diseases. Autonomic neuropathy. https://www.niddk.nih. gov/health-information/diabetes/overview/preventing- problems/nerve-damage-diabetic-neuropathies/autonomic- neuropathy. Accessed June 15, 2022.
15. Schäfer A, Flierl U, Bauersachs J. Anticoagulants for stroke prevention in heart failure with reduced ejection fraction. Clin Res Cardiol. 2022 Jan;111(1):1-13. doi: 10.1007/s00392- 021-01930-y. Epub 2021 Aug 27. PMID: 34448932; PMCID: PMC8766365.
16. Theresa A McDonagh and others, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726, https://doi.org/10.1093/eurheartj/ehab368